Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EndoFLIP for EGJOO Diagnosis and Botox Treatment
NCT04938102Withdrawn
- Sponsor
- University of Kansas Medical Center
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Randomised, open-label trial of botulinum toxin type A in esophagogastric junction outflow obstruction (EGJOO) (3 arms), sponsored by University of Kansas Medical Center. Primary endpoint: Symptom Resolution at 12 weeks. Planned start Jul 2022; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
esophagogastric junction outflow obstruction (EGJOO)
Beyond the preview
Go deeper on NCT04938102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04938102.